Vera Therapeutics annual return on equity
2022
2023
2024
2025
Vera Therapeutics Return on Equity (ROE) Growth & History (VERA)
Vera Therapeutics's return on equity was −50.71% for fiscal 2025.
View full Vera Therapeutics company overviewVera Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −50.71% | −5.88 pp |
| 2024 | 2024-12-31 | −44.83% | +62.67 pp |
| 2023 | 2023-12-31 | −107.50% | +14.08 pp |
| 2022 | 2022-12-31 | −121.58% | — |
Vera Therapeutics quarterly return on equity
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −24.13% | −8.87 pp |
| Q1 2026 | 2026-03-31 | −21.92% | −12.63 pp |
| Q4 2025 | 2025-12-31 | −18.16% | −8.13 pp |
| Q3 2025 | 2025-09-30 | −18.52% | −3.40 pp |
| Q2 2025 | 2025-06-30 | −15.26% | −5.36 pp |
| Q1 2025 | 2025-03-31 | −9.30% | +3.17 pp |
| Q4 2024 | 2024-12-31 | −10.03% | +12.74 pp |
| Q3 2024 | 2024-09-30 | −15.12% | +0.10 pp |
| Q2 2024 | 2024-06-30 | −9.89% | +3.63 pp |
| Q1 2024 | 2024-03-31 | −12.47% | +13.16 pp |
| Q4 2023 | 2023-12-31 | −22.76% | +12.76 pp |
| Q3 2023 | 2023-09-30 | −15.22% | +6.51 pp |
| Q2 2023 | 2023-06-30 | −13.52% | −1.91 pp |
| Q1 2023 | 2023-03-31 | −25.63% | −8.88 pp |
| Q4 2022 | 2022-12-31 | −35.53% | −13.80 pp |
| Q3 2022 | 2022-09-30 | −21.72% | −13.15 pp |
| Q2 2022 | 2022-06-30 | −11.61% | — |
| Q1 2022 | 2022-03-31 | −16.75% | — |
| Q4 2021 | 2021-12-31 | −21.73% | — |
| Q3 2021 | 2021-09-30 | −8.57% | — |
Vera Therapeutics return on equity trends
Between the periods ended 2022-12-31 and 2025-12-31, Vera Therapeutics's return on equity increased from −121.58% to −50.71%, a change of +70.87 percentage points. The latest reported quarter, Q2 2026, shows −24.13%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vera Therapeutics source filings ↗